

**6 March 2008**

## **PROSONIX APPOINTS DR JIM PHILLIPS AS NON EXECUTIVE CHAIRMAN**

*Prosonix (Oxford, UK) leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries, are delighted to announce the appointment of Dr Jim Phillips to the key post of Non-Executive Chairman.*

*Jim has over 20 years healthcare industry experience and is also a qualified physician with an MBA from Cass Business School, having extensive first hand experience in business development in pharmaceuticals, and in developing early stage ventures.*

*He has worked for Johnson & Johnson, and Novartis in Senior Executive roles, and was Founder & Chief Executive officer of Talisker Pharmaceuticals Ltd, which was acquired by EUSA Pharma Inc in July 2006 giving investors a successful exit.*

*As Chief Executive, Jim also took Bone Medical Ltd through its oversubscribed IPO in Australia in 2004. In addition he has held a number of other international board level roles including organizations such as West Sussex Health Authority, Lifeguard Technologies Ltd, CRF Inc, Diabetology Ltd, EUSA Pharma Inc, Opi S.A.*

Commenting on his appointment David Hipkiss, Prosonix CEO said

*"I am delighted for Prosonix to have been able to have secured the services of Jim to accelerate us through our next stage of corporate development. He is an outstanding and key recruit with a proven track record of sustainable value generation in the life science sector."*


*Adding his approval Dr Phillips said,*

*"Prosonix have demonstrated that it has world-leading particle engineering capabilities which have particular utility in the pharmaceutical life science sector. I am looking forward to be able to assist David and his team at Prosonix in expanding its application in the pharmaceutical and chemical industries, and generating long term value for our stakeholders and customers alike."*

**For more Information contact:**

**Prosonix**  
**David Hipkiss**  
CEO  
Prosonix Ltd  
Magdalen Centre  
Oxford Science Park  
Oxford  
OX4 4GA, UK

Tel + 44 (0) 1865 784250  
Web [www.prosonix.co.uk](http://www.prosonix.co.uk)



## Notes for Editors

### About Prosonix Ltd

[www.prosonix.co.uk](http://www.prosonix.co.uk)

Based in Oxford UK and Experts in Sound Science™, Prosonix are acknowledged leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries

Prosonix's team of chemists and engineers combine to give Prosonix a unique multidisciplinary approach and competitive advantage to solve customers complex process problems, leveraging its proprietary intellectual property and patented ultrasonic processing equipment to deliver long term and sustainable value.

Prosonix's core markets to date have been in the Pharmaceutical and Chemical industries, securing over 50 worldwide customers

Prosonitron™, Prosonix's world leading and patented sonocrystallization process and reactor technology is already proven across scale, facilitating the Complete Crystallization Control™ of many aspects of complex pharmaceutical crystallization processes, including control of crystal size, shape, purity, the selective production of polymorphs, enhancing both manufacturing productivity and ultimate formulation performance. Additionally Prosonitron™ has broad application for process intensification in the wider chemical industry.

SAX™, a new and award winning sonocrystallization development, is a novel ultrasonic particle engineering and drug delivery process technology with world beating potential. In combination with the Prosonitron™ technology the SAX™ process can produce highly engineered single and combination microcrystalline drug particles that are ideally suited for inhalation, without the need for destructive milling or micronisation processes; SAX™ particles have better stability, formulation consistency, and potentially improved efficacy per unit dose than those made by other techniques. SAX™ was exclusively licensed from the University of Bath, (Bath, UK) in January 2007.

In January 2008 Prosonix entered into a worldwide exclusive license deal with Rafael Industries (Haifa, Israel) for Rafael's patented and proprietary ultrasonic particle rounding technology (PRT). Importantly the PRT patent is already granted in key geographies and has wide ranging utility independent of the method of ultrasound delivery in secondary particle engineering, post initial crystallization and isolation. Key applications include particle rounding to improve product flowability and rheology, compressibility, and added concomitant benefits in formulation performance and assurance. Additional opportunities in taste masking, coating, and granulation are also emerging. Used in combination, the PRT process technology and the proven Prosonix Prosonitron™ process and reactor technology represents an ideal solution to a range of common secondary pharmaceutical manufacturing problems, and overcomes many of the problems hitherto associated with classical dry milling or micronisation.

Underpinning Prosonix's leadership in commercializable crystallization technology is CrystalGEM™, an award winning predictive crystallization service that significantly enhances crystallization screening productivity in pharmaceutical development and SonoLab™, a suite of designed for purpose small scale reactors that can be used by the laboratory chemist with confidence, knowing that a proven scale up method already exists. CrystalGEM™ is marketed under a sole licence agreement from Chiralabs Ltd (Oxford, UK).

Complementing its market led internal R&D programs, Prosonix is also actively engaged with several strategic partnerships with leading academic and technology institutions, including at present the University of Bath, University of Coventry, and the University of Leeds.

